Delivery Order SPE2DB22D2206-SPE2DB25FJT45
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract valued at $3,513.96, with an ultimate completion date of August 11, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract with a ceiling value of $24,364.10 and an ultimate completion date of July 22, 2025. This is a non-set-aside competitive award, with performance to be executed at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed-price contract valued at $8,401.76, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award was issued on August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $43,495.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). The contract, which represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, carries an ultimate completion date of September 4, 2025, and involves no set-aside designation, indicating competitive award status. Performance will be executed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,434.78 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Xifaxan is a gastrointestinal antibiotic commonly used to treat traveler's...
- The Defense Logistics Agency awarded a delivery order valued at $24,690.56 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor for delivery to the Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJT45Delivery Order
The Defense Logistics Agency (DLA) awarded a $25,962.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, reflecting the vendor's established capability to meet federal pharmaceutical procurement requirements. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of pharmaceutical products across multiple therapeutic domains and has demonstrated consistent performance in fulfilling federal medical supply needs through open competition. The DLA Medical Supply Chain utilizes AmerisourceBergen's prime vendor agreement to ensure reliable access to both brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. This particular delivery order for Xifaxan, an antibiotic medication, exemplifies the routine pharmaceutical resupply operations conducted under the broader vendor agreement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.0k | 9/3/25 |